0001246360-15-000989.txt : 20150219 0001246360-15-000989.hdr.sgml : 20150219 20150219162109 ACCESSION NUMBER: 0001246360-15-000989 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150217 FILED AS OF DATE: 20150219 DATE AS OF CHANGE: 20150219 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SYNAGEVA BIOPHARMA CORP CENTRAL INDEX KEY: 0000911326 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 561808663 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 33 HAYDEN AVE. CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: (781) 357-9900 MAIL ADDRESS: STREET 1: 33 HAYDEN AVE. CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: TRIMERIS INC DATE OF NAME CHANGE: 19970516 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BOESS CARSTEN CENTRAL INDEX KEY: 0001277495 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-23155 FILM NUMBER: 15632018 MAIL ADDRESS: STREET 1: C/O ALEXION PHARMACEUTICALS STREET 2: 352 KNOTTER DR CITY: CHESHIRE STATE: CT ZIP: 06410 4 1 form.xml PRIMARY DOCUMENT X0306 4 2015-02-17 false 0000911326 SYNAGEVA BIOPHARMA CORP GEVA 0001277495 BOESS CARSTEN 33 HAYDEN AVE LEXINGTON MA 02421 false true false false SVP, Chief Financial Officer Common Stock 2015-02-17 4 M false 13235 1.7 A 13235 D Common Stock 2015-02-17 4 M false 29062 40.74 A 42297 D Common Stock 2015-02-17 4 S false 8989 98.85 D 33308 D Common Stock 2015-02-17 4 S false 14750 99.97 D 18558 D Common Stock 2015-02-17 4 S false 16716 100.74 D 1842 D Common Stock 2015-02-17 4 S false 1842 101.69 D 0 D Stock Option (Right to Buy) 1.7 2015-02-17 4 M false 13235 0 D 2021-05-25 Common Stock 13235 9929 D Stock Option (Right to Buy) 40.74 2015-02-17 4 M false 29062 0 D 2022-06-27 Common Stock 29062 15938 D The stock option exercise and sale of shares of the Company's common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 24, 2014. The Stock Option granted the reporting person an option to purchase 158,840 shares of the Company's common stock (the "Shares"). 25% of the Shares vested and became exercisable on 05/16/2012, and 1/36 of the remainder of the Shares vest and become exercisable monthly thereafter. The Stock Option granted the reporting person an option to purchase 45,000 shares of the Company's common stock (the "Shares"). 25% of the Shares vested and became exercisable on 06/27/ 2013 and 1/36 of the remainder of the Shares vest and become exercisable monthly thereafter. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $98.34 to $99.32. The price reported in this row reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $99.36 to $100.35. The price reported in this row reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $100.45 to $101.37. The price reported in this row reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $101.56 to $101.97. The price reported in this row reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. /s/ Carsten Boess 2015-02-19